In a patient on chronic stable methadone or buprenorphine for OUD who develops symptomatic central sleep apnea, do you prioritize treating the CSA (CPAP → ASV if LVEF >45%, adjunct acetazolamide/O₂) or pushing the opioid team toward dose reduction? Where does loop-gain phenotyping change your sequence?